T-DM1 Extends Survival in HER2+ Breast Cancer.
Results from the phase III TH3RESA study show that T-DM1 is effective in patients with metastatic HER2-positive breast cancer that has progressed despite two or more HER2-targeted therapies, extending their median overall survival by nearly 7 months.